BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33976366)

  • 21. Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.
    Cheong CM; Mrozik KM; Hewett DR; Bell E; Panagopoulos V; Noll JE; Licht JD; Gronthos S; Zannettino ACW; Vandyke K
    Cancer Lett; 2020 Apr; 475():99-108. PubMed ID: 32014459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The histone methyltransferase, NSD2, enhances androgen receptor-mediated transcription.
    Kang HB; Choi Y; Lee JM; Choi KC; Kim HC; Yoo JY; Lee YH; Yoon HG
    FEBS Lett; 2009 Jun; 583(12):1880-6. PubMed ID: 19481544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
    Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA
    Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.
    Gautam N; Kaur M; Kaur S
    J Cancer Res Ther; 2021; 17(2):311-326. PubMed ID: 33063698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
    Chen H; Tu SW; Hsieh JT
    J Biol Chem; 2005 Jun; 280(23):22437-44. PubMed ID: 15817459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
    Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
    Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LncRNA MEG3 inhibits the progression of prostate cancer by facilitating H3K27 trimethylation of EN2 through binding to EZH2.
    Zhou Y; Yang H; Xia W; Cui L; Xu R; Lu H; Xue D; Tian Z; Ding T; Cao Y; Shi Q; He X
    J Biochem; 2020 Mar; 167(3):295-301. PubMed ID: 31790140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling.
    Wang JJ; Zou JX; Wang H; Duan ZJ; Wang HB; Chen P; Liu PQ; Xu JZ; Chen HW
    Acta Pharmacol Sin; 2019 Aug; 40(8):1067-1075. PubMed ID: 30670815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases.
    Li W; Tian W; Yuan G; Deng P; Sengupta D; Cheng Z; Cao Y; Ren J; Qin Y; Zhou Y; Jia Y; Gozani O; Patel DJ; Wang Z
    Nature; 2021 Feb; 590(7846):498-503. PubMed ID: 33361816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro.
    Cohen AS; Yap DB; Lewis ME; Chijiwa C; Ramos-Arroyo MA; Tkachenko N; Milano V; Fradin M; McKinnon ML; Townsend KN; Xu J; Van Allen MI; Ross CJ; Dobyns WB; Weaver DD; Gibson WT
    Hum Mutat; 2016 Mar; 37(3):301-7. PubMed ID: 26694085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-144 Suppresses Prostate Cancer Growth and Metastasis by Targeting EZH2.
    Sun XB; Chen YW; Yao QS; Chen XH; He M; Chen CB; Yang Y; Gong XX; Huang L
    Technol Cancer Res Treat; 2021; 20():1533033821989817. PubMed ID: 33550923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
    Tellez CS; Picchi MA; Juri D; Do K; Desai DH; Amin SG; Hutt JA; Filipczak PT; Belinsky SA
    Clin Epigenetics; 2021 Feb; 13(1):44. PubMed ID: 33632299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex.
    Duan Z; Zou JX; Yang P; Wang Y; Borowsky AD; Gao AC; Chen HW
    Prostate; 2013 Apr; 73(5):455-66. PubMed ID: 23038103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NSD2 inhibition suppresses metastasis in cervical cancer by promoting TGF-β/TGF-βRI/SMADs signaling.
    Zhu L; Yu CL; Zheng Y
    Biochem Biophys Res Commun; 2019 Nov; 519(3):489-496. PubMed ID: 31526565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer.
    Bohrer LR; Chen S; Hallstrom TC; Huang H
    Endocrinology; 2010 Nov; 151(11):5136-45. PubMed ID: 20881251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone-modifying genes as biomarkers in hepatocellular carcinoma.
    Hung SY; Lin HH; Yeh KT; Chang JG
    Int J Clin Exp Pathol; 2014; 7(5):2496-507. PubMed ID: 24966962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
    Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
    Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.
    Matsubara T; Toyokawa G; Takada K; Kinoshita F; Kozuma Y; Akamine T; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Mori M
    PLoS One; 2019; 14(5):e0215103. PubMed ID: 31042721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
    Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
    Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.